Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
irinotecan/脳卒中
リンクがクリップボードに保存されます
12 結果
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.
登録ユーザーのみが記事を翻訳できます
ログインサインアップ
OBJECTIVE
The efficacy of cisplatin, irinotecan, and bevacizumab was evaluated in patients with extensive-stage small-cell lung cancer (ES-SCLC).
METHODS
Patients with ES-SCLC received cisplatin 30 mg/m(2) and irinotecan 65 mg/m(2) on days 1 and 8 plus bevacizumab 15 mg/kg on day 1 every 21 days for
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND
Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC). There are, however, no data about the use of the XELIRI regimen in the neoadjuvant treatment.
METHODS
Patients with unresectable
Case report on 5-fluorouracil induced cerebrovascular accident
登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Introduction: 5-Fluorouracil is an antineoplastic agent generally used to treat various types of solid tumors. The common adverse drug reaction associated with 5-fluorouracil are myelosuppression, mucositis, diarrhea, and hand-foot
The resolution of carotid arterial thrombus by oral anticoagulation after IV thrombolysis for chemotherapy-induced stroke: A case report
登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Rationale: Cancer-related stroke has been regarded as an emerging subtype of ischemic event. Acute treatment for this subtype may include the antiplatelet agents, anticoagulants, or endovascular intervention.
A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer.
登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND
The objectives of the current study were to evaluate the safety and efficacy of gemcitabine and irinotecan (Irinogem) in patients with metastatic bladder cancer. Irinotecan and gemcitabine are newer-generation chemotherapeutic agents with different mechanisms of action, nonoverlapping
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
登録ユーザーのみが記事を翻訳できます
ログインサインアップ
OBJECTIVE
Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements in survival seen following currently available salvage therapy. This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizumab, and a cytotoxic agent, irinotecan, is
FOLFIRINOX-induced reversible dysarthria: A case report and review of previous cases.
登録ユーザーのみが記事を翻訳できます
ログインサインアップ
FOLFIRINOX is a standard chemotherapeutic regimen for patients with advanced pancreatic cancer who have a good performance status. In this study, we present the case of a 64-year-old male who developed dysarthria following FOLFIRINOX treatment, and review all four cases of dysarthria encountered
Targeting the EWS-FLI1 transcription factor in Ewing sarcoma.
登録ユーザーのみが記事を翻訳できます
ログインサインアップ
OBJECTIVE
Preclinical data indicate there is strong synergism of action against Ewing sarcoma in sequential treatment with trabectedin followed by irinotecan and it appears to be related to a selective blockade of the transcription factor EWS-FLI1. This combination was evaluated in Ewing sarcoma
Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.
登録ユーザーのみが記事を翻訳できます
ログインサインアップ
OBJECTIVE
Clinical trials have shown that adding bevacizumab to cytotoxic chemotherapy improves survival for patients with colorectal cancer, although its effectiveness in the Medicare population is uncertain.
METHODS
Using the Surveillance, Epidemiology, and End Results (SEER) -Medicare linked
[Cases of three patients undergoing chemotherapy for gastric cancer who developed Trousseau's syndrome].
登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Trousseau's syndrome involves unexplained thrombotic events along with malignancy. We report the cases of 3 patients undergoing chemotherapy for gastric cancer in whom Trousseau's syndrome occurred. Case 1 involved a 43-year-old woman undergoing S-1/cisplatin( CDDP) combination therapy as first-line
Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.
登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Aflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in the second‑line therapy of patients with metastatic colorectal cancer (mCRC). In this study, we evaluated the effects of aflibercept in first‑line therapy with FOLFOX followed by maintenance with
Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen").
登録ユーザーのみが記事を翻訳できます
ログインサインアップ
The roots of Salvia miltiorrhiza ("Danshen") are used in traditional Chinese medicine for the treatment of numerous ailments including cardiovascular disease, hypertension, and ischemic stroke. Extracts of S. miltiorrhiza roots in the formulation "Compound Danshen Dripping Pill" are undergoing
科学に裏打ちされた最も完全な薬草データベース
- 55の言語で動作します
- 科学に裏打ちされたハーブ療法
- 画像によるハーブの認識
- インタラクティブGPSマップ-場所にハーブをタグ付け（近日公開）
- 検索に関連する科学出版物を読む
- それらの効果によって薬草を検索する
- あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください
症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています
